M&A Deal Summary

Lannett Company Acquires Kremers Urban Pharmaceuticals

On November 27, 2015, Lannett Company acquired life science company Kremers Urban Pharmaceuticals from UCB for 1.2B USD

Acquisition Highlights
  • This is Lannett Company’s 1st transaction in the Life Science sector.
  • This is Lannett Company’s largest (disclosed) transaction.
  • This is Lannett Company’s 2nd transaction in the United States.
  • This is Lannett Company’s 1st transaction in New Jersey.

M&A Deal Summary
Date 2015-11-27
Target Kremers Urban Pharmaceuticals
Sector Life Science
Buyer(s) Lannett Company
Sellers(s) UCB
Deal Type Divestiture
Deal Value 1.2B USD

Target

Kremers Urban Pharmaceuticals

Princeton, New Jersey, United States
website
Kremers Urban Pharmaceuticals, Inc. is a specialty generic pharmaceuticals company.

Search 192,611 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Lannett Company

Trevose, Pennsylvania, United States

website

Category Company
Founded 1942
Sector Medical Products
Employees810
Revenue 479M USD (2021)
DESCRIPTION

Lannett Company is a developer, manufacturer, packager, marketer and distributor of generic pharmaceutical products for a wide range of medical indications. Lannett Company was founded in 1942 and is based in Trevose, Pennsylvania.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (New Jersey) 1 of 1
Country (United States) 2 of 2
Year (2015) 2 of 2
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-06-02 Silarx Pharmaceuticals

Carmel, New York, United States

Silarx Pharmaceuticals, Inc. is a manufacturer and marketer of high-quality liquid pharmaceutical products, including generic prescription and over-the-counter products.

Buy -

Seller(S) 1

SELLER

UCB

Brussels, Belgium

website

Category Company
Founded 1928
Sector Healthcare Services
Employees7,600
Revenue 5.3B EUR (2020)
DESCRIPTION

UCB is a biopharma focused on severe diseases with operations in approximately 40 countries. UCB incorporated in 1928 and is based in Brussels, Belgium.

DEAL STATS #
Overall 4 of 7
Sector (Life Science) 4 of 6
Type (Divestiture) 3 of 6
State (New Jersey) 1 of 1
Country (United States) 1 of 1
Year (2015) 1 of 1
Size (of disclosed) 1 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-11-22 Lectus Therapeutics - Pharmaceutical Assets

United Kingdom

Lectus Therapeutics - Pharmaceutical Assets engages in the discovery and development of Lectus' drug for the treatment of central nervous system. LEPTICS technology to identify compounds in a new area of chemical space. Such compounds are anticipated to possess a novel mechanism of action mediated through an effect on ion channel accessory proteins.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-02-01 UCB - Three Cardiovascular Products

Belgium

UCB - Three Cardiovascular Products consists of Elantan®, Isoket® and Deponit® rights is a producer of medical products to treat both acute and chronic coronary artery disease.

Sell €92M
Mergr

Product

Company

Legal